• Jussi Sarin, Reidar Grénman, Kalle Aitasalo, and Jaakko Pulkkinen.
• Department of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.
• Ann Oto Rhinol Laryn. 2012 Sep 1; 121 (9): 563-9.

ObjectivesWe evaluated the results of cases of chronic otitis media treated with mastoid obliteration surgery using bioactive glass S53P4.MethodsTwenty-five patients with chronic otitis media and 1 patient with cerebrospinal fluid leakage without chronic infection were treated with bioactive glass S53P4. Twenty patients had had previous surgery because of chronic otitis media with or without cholesteatoma. A mastoid obliteration was performed with bioactive glass S53P4 granules and a musculoperiosteal flap with or without bone paté. In 2 patients with a bony dehiscence at the middle cranial fossa, a bioactive glass plate was used to support the protruding dura. In addition, in 3 patients, occlusion of a dural fistula was needed The median follow-up period was 34.5 months (range, 1 to 182 months).ResultsExcluding the 2 patients with only 1 month of follow-up at our department, 96% of the patients had a dry, safe ear or only intermittent otorrhea. In 92% of the patients, the objective of achieving a smaller or nonexistent cavity was achieved.ConclusionsBioactive glass S53P4 is a noteworthy material in mastoid obliteration surgery.

22 keywords...

hide…